Table 1.
Relationship between OCT1 immunoreactivity and clinicopathological parameters in ER-positive breast cancer patients.
| OCT1 Status | p-Value | |||
|---|---|---|---|---|
| Positive IR (n = 48) |
Negative IR (n = 60) |
|||
| Age | ≤50 years old | 26 | 27 | 0.344 |
| >50 years old | 22 | 33 | ||
| Stage | I | 17 | 25 | 0.508 |
| II, III | 31 | 35 | ||
| Invasive tumor size | ≤20 mm | 26 | 34 | 0.795 |
| >20 mm | 22 | 26 | ||
| Lymph node status | Positive | 21 | 22 | 0.455 |
| Negative | 27 | 38 | ||
| Nuclear grade | 1 | 24 | 36 | 0.299 |
| 2, 3 | 24 | 24 | ||
| PgR status | Positive | 40 | 52 | 0.628 |
| Negative | 8 | 8 | ||
| HER2 status | Positive | 6 | 8 | 0.898 |
| Negative | 42 | 52 | ||
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IR, immunoreactivity; PgR, progesterone receptor.